



BlueCross BlueShield
of Alabama

Name of Blue Advantage Policy:

Laparoscopic, and Percutaneous, and Transcervical Techniques for the Myolysis of Uterine Fibroids

Policy #: 208
Category: Surgery

Latest Review Date: August 2019
Policy Grade: B

BACKGROUND:

Blue Advantage medical policy does not conflict with Local Coverage Determinations (LCDs), Local Medical Review Policies (LMRPs) or National Coverage Determinations (NCDs) or with coverage provisions in Medicare manuals, instructions or operational policy letters. In order to be covered by Blue Advantage the service shall be reasonable and necessary under Title XVIII of the Social Security Act, Section 1862(a)(1)(A). The service is considered reasonable and necessary if it is determined that the service is:

1. *Safe and effective;*
2. *Not experimental or investigational*;*
3. *Appropriate, including duration and frequency that is considered appropriate for the service, in terms of whether it is:*
 - *Furnished in accordance with accepted standards of medical practice for the diagnosis or treatment of the patient's condition or to improve the function of a malformed body member;*
 - *Furnished in a setting appropriate to the patient's medical needs and condition;*
 - *Ordered and furnished by qualified personnel;*
 - *One that meets, but does not exceed, the patient's medical need; and*
 - *At least as beneficial as an existing and available medically appropriate alternative.*

Routine costs of qualifying clinical trial services with dates of service on or after September 19, 2000 which meet the requirements of the Clinical Trials NCD are considered reasonable and necessary by Medicare. Providers should bill **Original Medicare for covered services that are related to **clinical trials** that meet Medicare requirements (Refer to Medicare National Coverage Determinations Manual, Chapter 1, Section 310 and Medicare Claims Processing Manual Chapter 32, Sections 69.0-69.11).*

POLICY:

Effective for dates of service on or after July 1, 2005:

Blue Advantage will treat laparoscopic, ~~and~~ percutaneous, and transcervical techniques of myolysis as a noncovered benefit for the treatment of uterine fibroids and as investigational.

Blue Advantage does not approve or deny procedures, services, testing, or equipment for our members. Our decisions concern coverage only. The decision of whether or not to have a certain test, treatment or procedure is one made between the physician and his/her patient. Blue Advantage administers benefits based on the members' contract and medical policies. Physicians should always exercise their best medical judgment in providing the care they feel is most appropriate for their patients. Needed care should not be delayed or refused because of a coverage determination.

DESCRIPTION OF PROCEDURE OR SERVICE:

Various minimally invasive treatments for uterine fibroids have been proposed as alternatives to surgery. Among these approaches are laparoscopic and percutaneous techniques to induce myolysis which includes radiofrequency volumetric thermal ablation (RFVTA), laser and bipolar needles, cryomyolysis and magnetic resonance imaging (MRI)-guided laser ablation.

Uterine Fibroids

Uterine fibroids, also known as leiomyomas, are among the most common conditions affecting women in the reproductive years; symptoms include menorrhagia, pelvic pressure, or pain.

Treatment

Surgery, including hysterectomy and various myomectomy procedures, is considered the criterion standard for symptom resolution. However, there is the potential for surgical complications and, in the case of hysterectomy, the uterus is not preserved. In addition, multiple myomectomy may be associated with longer operating time, postoperative febrile morbidity and development of pelvic adhesions. There has been longstanding research interest in developing minimally invasive alternatives for treating uterine fibroids, including procedures that retain the uterus and allow for future childbearing. Treatment options include uterine artery embolization (UAE) (see medical policy #022 – *Occlusion of Uterine Arteries using Transcatheter Embolization or Laparoscopic Occlusion to Treat Uterine Fibroids*) and magnetic resonance imaging guided focused ultrasound therapy (see medical policy #178 – *Magnetic Resonance Guided Focused Ultrasound*).

Various techniques to induce myolysis have also been studied including Nd:YAG lasers, bipolar electrodes, cryomyolysis and radiofrequency ablation. An energy source is used to create areas of necrosis within uterine fibroids, reducing their volume and thus relieving symptoms. Early methods involved the insertion of probes multiple times into the fibroid and were performed without imaging guidance. There were concerns about serosal injury and abdominopelvic adhesions with these techniques, possibly due to the multiple passes through the serosa needed to treat a single fibroid. Newer systems using radiofrequency energy do not require multiple repetitive insertions of needle electrodes. Ultrasonography is used laparoscopically to determine

the size and location of fibroids, to guide the probe, and to ensure the probe is in the correct location so that optimal energy is applied to the fibroid. Percutaneous and transcervical approaches using MRI guidance have also been reported.

KEY POINTS:

The most recent literature review was updated through March 18, 2020.

Summary of Evidence

For individuals who have symptomatic uterine fibroids who receive RFVTA, the evidence includes a randomized controlled trial (RCT) and systematic review. The relevant outcomes are symptoms, QOL, and treatment-related morbidity. The meta-analysis found low rates of reintervention with RFVTA and QOL outcomes that were similar to uterine artery embolization and myomectomy at 12 months. Data on reintervention rates at 36 months were limited to 1 study and no studies reported reintervention rates at 60 months. The RCT with a follow-up longer than three months found that RFVTA was noninferior to laparoscopic myomectomy on the trial's primary outcome: length of hospitalization. A number of secondary outcomes were reported at 12 and 24 months, including symptoms and QOL. None of the secondary outcomes demonstrated significant between-group differences in a subgroup analysis of 43 patients. Additional well designed RCTs with longer follow up are needed to determine the effect of RFVTA on health outcomes compared with other treatment options. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have uterine fibroids who receive transcervical fibroid ablation, the evidence includes a single cohort study, prospective and retrospective studies. The relevant outcomes are safety, efficacy, QOL, symptoms, and surgical reintervention. A retrospective 5 year study was completed, but it only included 23 women. There are no randomized controlled trials noted. Well-designed head to head trials with long term results are needed. Currently, the evidence is not sufficient to determine long term health outcomes for this procedure.

For individuals who have symptomatic uterine fibroids who receive laser or bipolar needles, the evidence includes case series. The relevant outcomes are symptoms, QOL, and treatment-related morbidity. The case series were published in the 1990s and the procedures utilized may not reflect current practice. RCTs comparing laser or bipolar needles to alternative treatments for uterine fibroids are needed to adequately evaluate the safety and efficacy of this technology. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have uterine fibroids who receive cryomyolysis, the evidence includes case series. The relevant outcomes are symptoms, QOL, and treatment-related morbidity. Among the few case series, sample sizes were small (≤ 20 patients). RCTs comparing cryomyolysis with alternative treatments for uterine fibroids are needed to evaluate the safety and efficacy of this technology adequately. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have uterine fibroids who receive MRI-guided laser ablation, the evidence includes a study with historical controls. The relevant outcomes are symptoms, QOL, and treatment-related morbidity. A single study with historical controls (N=66) is not sufficiently robust to evaluate the technology. RCTs comparing MRI-guided laser ablation to alternative treatments for uterine fibroids are needed to adequately evaluate the safety and efficacy of this technology. The evidence is insufficient to determine the effects of the technology on health outcomes.

Practice Guidelines and Position Statements

American College of Obstetricians and Gynecologists

In 2016, the American College of Obstetricians and Gynecologists reaffirmed a 2008 Practice Bulletin titled “Alternatives to Hysterectomy in the Management of Leiomyomas”.

Recommendations based on good and consistent scientific evidence are that abdominal myomectomy is a safe and effective treatment of women with symptomatic leiomyomas and that uterine artery embolization is a safe and effective option for appropriately selected women who wish to retain their uteri. The bulletin contains no recommendations regarding myolysis utilizing laparoscopic or percutaneous techniques.

U.S. Preventive Services Task Force

Not applicable

KEY WORDS:

Uterine fibroids, leiomyomata, hysterectomy, myomectomy, myolysis, Nd:YAG laser, bipolar electrodes, cryomyolysis, radiofrequency ablation, MRI guidance, laparoscopic procedure, percutaneous procedure, ExAblate®, Acessa, Halt, cryoablation, interstitial laser photocoagulation of uterine fibroids, laser myolysis, RFA, transcervical, sonata system

APPROVED BY GOVERNING BODIES:

In November 2012, the Acessa™ System (Acessa Health, Austin, TX, formerly Halt Medical) was cleared for marketing by the U.S. Food and Drug Administration (FDA). The device is indicated for percutaneous laparoscopic coagulation and ablation of soft tissue and treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance is one of the listed indications. The technology was previously approved in 2010 at which time it was called the Halt 2000GI™ Electrosurgical Radiofrequency Ablation System (Halt Medical; Brentwood, CA). In 2014, the ultrasound guidance system received marketing clearance from the FDA (K132744). In 2018, the third-generation Acessa™ ProVu System® was cleared for marketing by the FDA through the 510(k) process for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. (K181124).

In August 2018, the Sonata System (Gynesonics, Inc, Redwood City, CA) received 510(k) clearance.

Cryoablation is a surgical procedure that uses previously approved and available cryoablation systems; and as a surgical procedure, it is not subject to regulation by the FDA. Other products addressed in this review (e.g., Nd:YAG lasers, bipolar electrodes) have long-standing FDA approval, and there are not products specifically approved for the treatment of uterine fibroids.

BENEFIT APPLICATION:

Coverage is subject to member’s specific benefits. Group specific policy will supersede this policy when applicable.

CURRENT CODING:

CPT codes:

58674	Laparoscopy, surgical, ablation of uterine fibroid(s), including intraoperative ultrasound guidance and monitoring, radiofrequency
--------------	--

The following unlisted codes might be used for a laparoscopic procedure.

58578	Unlisted laparoscopy procedure, uterus
58999	Unlisted procedure, female genital system (non-obstetrical)

For percutaneous procedures, the following code would likely be used to describe the MRI imaging component of the procedure.

77022	Magnetic resonance guidance for, and monitoring of, parenchymal tissue ablation
--------------	---

For ultrasound guidance, one of the following codes might be used:

76940	Ultrasound guidance for and monitoring of, parenchymal tissue ablation
76998	Ultrasound guidance, intraoperative

For transcervical fibroid ablation:

0404T	Transcervical uterine fibroid(s) ablation with ultrasound guidance, radiofrequency
--------------	--

PREVIOUS CODING:

CPT Codes

0336T	Laparoscopy, surgical, ablation of uterine fibroid(s), including intraoperative ultrasound guidance and monitoring, radiofrequency (Deleted 12/31/16)
--------------	--

REFERENCES:

1. American College of Obstetricians and Gynecologists (ACOG). Alternatives to hysterectomy in the management of leiomyomas. ACOG practice bulletin; no. 96. Available online at: www.guideline.gov. Accessed July 23, 2018.
2. American College of Obstetricians Gynecologists. ACOG practice bulletin. Alternatives to hysterectomy in the management of leiomyomas. *Obstet Gynecol*. Aug 2008; 112(2 Pt 1):387-400.
3. Bergamini V, Ghezzi F, Cromi A, Bellini G, et al. Laparoscopic radiofrequency thermal ablation: A new approach to symptomatic uterine myomas. *Am J Obstet Gynecol*, March 2005; 192(3): 768-773.
4. Berman JM, Bolnick MD, Pemueller RR, et al. Reproductive outcomes in women following radiofrequency volumetric thermal ablation of symptomatic fibroids. *Journal of Reproductive Medicine*, May-June 2015; 60(5-6): 194-198.
5. Berman JM, Guido RS, Garza Leal JG et al. Three-Year Outcome of the Halt Trial: A Prospective Analysis of Radiofrequency Volumetric Thermal Ablation of Myomas. *J Minim Invasive Gynecol*. 2014 Mar 5. pii: S1553-4650(14)00194-0.
6. Bongers M, Gupta J, Garza-Leal JG, et al. The integrity trial: Preservation of uterine wall integrity 12 months after transcervical fibroid ablation with the sonata system. *J Gynecol Surg*. 2019 Oct 1;35(5):299-303.
7. Brucker SY, Hahn M, Kraemer D et al. Laparoscopic radiofrequency volumetric thermal ablation of fibroids versus laparoscopic myomectomy. *Int J Gynaecol Obstet*. 2014 Jun; 125(3):261-5.
8. Chapman R. New therapeutic technique for treatment of uterine leiomyomas using laser-induced interstitial thermotherapy (LITT) by a minimally invasive method, *Lasers in Surgery and Medicine*, January 1998; 22(3): 171-178.
9. Chudnoff SG, Berman JM, Levine DJ et al. Outpatient procedure for the treatment and relief of symptomatic uterine myomas. *Obstet Gynecol* 2013; 121(5):1075-82.
10. Chudnoff S, Guido R, Roy K, et al. Ultrasound-guided transcervical ablation of uterine leiomyomas. *Obstet Gynecol*. 2019 Jan;133(1):13-22.
11. Cowan B, et al. Interventional magnetic resonance imaging cryotherapy of uterine fibroid tumors: Preliminary observation, *American Journal of Obstetrics and Gynecology* 2002; 186: 1183-1187.
12. Donnez J, et al. Laparoscopic myolysis. *Human Reproduction Update* 2000; 6(6): 609-613.
13. Food and Drug Administration. Sonata System FDA clearance. Available at: www.accessdata.fda.gov/cdrh_docs/pdf17/K173703.pdf.
14. Galen DI, Pemueller RR, Leal JG et al. Laparoscopic radiofrequency fibroid ablation: phase II and phase III results. *JLS* 2014, 18:182-192.
15. Garza-Leal JG. Long term clinical outcomes of transcervical radiofrequency ablation of uterine fibroids: the vitality study. *J Gynecol Surg*. 2019 Feb 1;35(1):19-23.
16. Garza Leal JG, Hernandez Leon I, Castillo Saenz L et al. Laparoscopic ultrasound-guided radiofrequency volumetric thermal ablation of symptomatic uterine leiomyomas: feasibility study using the Halt 2000 Ablation System. *J Minim Invasive Gynecol* 2011; 18(3):364-71.
17. Ghezzi F, Cromi A, Bergamini V, Scarperi S, Bolis P and Franchi M. Midterm outcome of radiofrequency thermal ablation for symptomatic uterine myomas. *Surg Endosc*, November 2007; 21(11): 2081-2085.

18. Goldfarb HA. Bipolar laparoscopic needles for myoma coagulation, *Journal of the American Association of Gynecologic Laparoscopists*, February 1995; 2(2): 175-179.
19. Goldfarb HA. Myoma coagulation (myolysis), *Obstetrics and Gynecology Clinics*, June 2000, Vol. 27, No. 2.
20. Goldfarb HA. Nd:YAG laser laparoscopic coagulation of symptomatic myomas, *Journal of Reproductive Medicine*, July 1992; 37(7): 636-638.
21. Grube, MM, Neis, FF, Brucker, SS. Uterine Fibroids - Current Trends and Strategies. *Surg Technol Int*, 2019 Mar 20;34:257-263.
22. Guido RS, Macer J, Abbott K, Falls JL, Tilley IB, Chudnoff SG. Prospective analysis of the 24-month outcome from the IDE trial. *Health and Quality of Life Outcomes* 2013, 11:139.
23. Hahn M, Brucker S, Kraemer D et al. Radiofrequency volumetric thermal ablation of fibroids and laparoscopic myomectomy: Long term follow up from a randomized trial. *GebFra Science*, 2015, 75:442-449.
24. Hahn M, Brucker S, Kraemer D, et al. Radiofrequency volumetric thermal ablation of fibroids and laparoscopic myomectomy: long-term follow-up from a randomized trial. *Geburtshilfe Frauenheilkd*. May 2015; 75(5):442-449.
25. Havryliuk Y, Setton R, Carlow JJ, et al. Symptomatic fibroid management: Systematic review of the literature. *JSLs July-Sept 2017*; 21(3) e2017.00041.
26. Havryliuk, YY, Setton, RR, Carlow, JJ, Shaktman, BB. Symptomatic Fibroid Management: Systematic Review of the Literature. *JSLs*, 2017 Sep 28;21(3).
27. Hindley JT, et al. Clinical outcomes following percutaneous magnetic resonance image guided laser ablation of symptomatic uterine fibroids, *Human Reproduction* 2002, Vol., 17, No. 10, pp. 2737-2741.
28. Horowitz I. What's new in gynecology and obstetrics, *Journal of the American College of Surgeons*, October 2003; 197(4): 612-619.
29. Hudgens J, Johns DA, Lukes AS, et al. 12 month outcomes of the US patient cohort in the sonata ivotal IDE trial of transcervical ablation of uterine fibroids. *Int J Womens Health*. 2019 Jul5;11:387-394.
30. Jones S, O'Donovan P, Toub D. Radiofrequency ablation for treatment of symptomatic uterine fibroids. *Obstet Gynecol Int* 2012; 2012:194839.
31. Keltz J, Levie M, Chudnoff S. Pregnancy outcomes after direct uterine myoma thermal ablation: review of the literature. *J Minim Invasive Gynecol*. May - Jun 2017; 24(4):538-545.
32. Kim HS, Tsai J, Jacobs MA and Kamel IR. Percutaneous image-guided radiofrequency thermal ablation for large symptomatic uterine leiomyomata after uterine artery embolization: A feasibility and safety study. *J Vasc Interv Radiol*, January 2007; 18(1 Pt 1): 41-8.
33. Kolankaya A and Arici A. Myomas and assisted reproductive technologies: When and how to act? *Obstet Bynecol Clin North Am*, March 2006; 33(1): 145-152.
34. Kramer B, Hahn M, Taran FA, et al. Interim analysis of a randomized controlled trial comparing laparoscopic radiofrequency volumetric thermal ablation of uterine fibroids with laparoscopic myomectomy. *Int J Gynaecol Obstet*. May 2016; 133(2):206-211.
35. Law P, et al. Interstitial thermo-ablation under MRI guidance for the treatment of fibroids, *Current Opinion in Obstetrics and Gynecology*, August 2000; 12(4): 277-282.
36. Law P, et al. Magnetic resonance-guided percutaneous laser ablation of uterine fibroids, *Journal of Magnetic Resonance Imaging*, October 2000; 12(4): 565-570.

37. Lefebvre G, et al. The management of uterine leiomyomas, *Journal of Obstetrics and Gynecology Canada*, May 2003; 25(5): 396-418.
38. Lin, LL, Ma, HH, Wang, JJ. Quality of Life, Adverse Events, and Reintervention Outcomes after Laparoscopic Radiofrequency Ablation for Symptomatic Uterine Fibroids: A Meta-Analysis. *J Minim Invasive Gynecol*, 2018 Sep 27;26(3).
39. Myers E, et al. Management of uterine leiomyomata; What do we really know?, *Obstetrics and Gynecology*, July 2002, Vol. 100, No. 1, pp. 8-17.
40. Nisolle M, et al. Laparoscopic myolysis with the Nd:YAG laser, *Journal of Gynecologic Surgery*, July 1993; 9(2): 95-99.
41. Olive D. New approaches to the management of fibroids, *Obstetrics and Gynecology Clinics*, September 2000, Vol. 27, No. 3.
42. Olive DL, Lindheim SR and Pritts EA. Conservative surgical management of uterine myomas. *Obstetrics and Gynecology Clinics*, March 2006, vol. 33, No. 1.
43. Phillips DR, Nathanson HG, Milim SJ et al. Laparoscopic Leiomyoma Coagulation. *J Am Assoc Gynecol Laparosc* 1996; 3(4, Supplement):S39.
44. Robles R, Aguirre VA, Argueta AL, Guerrero MR. Confirmation of results of an earlier study assessing the safety and efficacy of a laparoscopic RF volumetric thermal ablation system. *Intl J of Gynecol and Obstetrics* 2013; Vol. 120, No. 1:65-69.
45. Sandberg EM, Tummers F, Cohen SL, et al. Reintervention risk and quality of life outcomes after uterine-sparing interventions for fibroids: a systematic review and meta-analysis. *Fertil Steril*. Apr 2018;109(4):698-707 e691.
46. Taheri, MM, Galo, LL, Potts, CC. Nonresective treatments for uterine fibroids: a systematic review of uterine and fibroid volume reductions. *Int J Hyperthermia*, 2019 Jan 25;36(1).
47. Toub DB. A new paradigm for uterine fibroid treatment: Transcervical, intrauterine sonography-guided radiofrequency ablation of uterin efibrids with the sonata system. *Curr Obstet Gynecol Rep*. 2017;6(1):67-73.
48. Vilos GA, Allaire C, Laberge PY, et al. The management of uterine leiomyomas. *J Obstet Gynaecol Can*. Feb 2015; 37(2):157-181.
49. Visvanathan D, et al. Interstitial laser photocoagulation for uterine myomas, *American Journal of Obstetrics and Gynecology* 2002, Vol. 187, No. 2, pp. 382-384.
50. Yin G, Chen M, Yang S, et al. Treatment of uterine myomas by radiofrequency thermal ablation: a 10-year retrospective cohort study. *Reprod Sci*. May 2015; 22(5):609-614.
51. Zreik TG, et al. Cryomyolysis, a new procedure for the conservative treatment of uterine fibroids, *Journal of the American Association of Gynecologic Laparoscopists*, February 1998; 5(1): 33-38.
52. Zupi E, Marconi D, Sbracia M et al. Directed laparoscopic cryomyolysis for symptomatic leiomyomata: one-year follow up. *J Minim Invasive Gynecol* 2005; 12(4):343-6.
53. Zupi E, Piredda A, Marconi D, et al. Directed laparoscopic cryomyolysis: A possible alternative to myomectomy and/or hysterectomy for symptomatic leiomyomas, *American Journal of Obstetrics and Gynecology* 2004, Vol. 190, pp. 639-643.

POLICY HISTORY:

Adopted for Blue Advantage, March 2005
 Available for comment May 1-June 14, 2005
 Medical Policy Group, October 2006

Medical Policy Group, October 2008
Medical Policy Group, October 2010
Medical Policy Group, September 2012: Active Policy but no longer scheduled for regular literature reviews and updates.
Medical Policy Group, September 2013
Medical Policy Group, December 2013
Medical Policy Group, April 2014
Medical Policy Group, July 2014
Medical Policy Group, July 2015
Medical Policy Group, August 2016
Medical Policy Group, December 2016
Medical Policy Group, August 2017
Medical Policy Group, August 2018 **(4)**: Updates to Key Points, Approved by Governing Bodies, and References. No change to policy statement.
Medical Policy Group, August 2019
Medical Policy Group, March 2020: Added CPT code 0404T.

This medical policy is not an authorization, certification, explanation of benefits, or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member's plan in effect as of the date services are rendered. All medical policies are based on (i) research of current medical literature and (ii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.

This policy is intended to be used for adjudication of claims (including pre-admission certification, pre-determinations, and pre-procedure review) in Blue Cross and Blue Shield's administration of plan contracts.